Company Encyclopedia
View More
name
Barinthus Biotherapeutics
BRNS.US
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunotherapeutic candidate for prostate cancer; VTP-600, an immunotherapeutic candidate targeting MAGE-A3 and NY-ESO1 antigens; VTP-500, a prophylactic vaccine candidate to prevent middle east respiratory syndrome; VTP-400, a prophylactic vaccine candidate for shingles; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023.
1.896 T
BRNS.USMarket value -Rank by Market Cap -/-

Financial Score

18/11/2025 Update
D
BiotechnologyIndustry
Industry Ranking304/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-62.26%E
    • Profit Margin0.00%D
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-100.00%E
    • Net Profit YoY-31.22%D
    • Total Assets YoY-42.13%E
    • Net Assets YoY-46.97%E
  • Cash ScoreE
    • Cash Flow Margin0.00%D
    • OCF YoY-100.00%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio22.56%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Buy Rating for Barinthus Biotherapeutics: Promising Clinical Developments and Strategic Merger with Clywedog Therapeutics

    H.C. Wainwright analyst Yi Chen reiterated a Buy rating for Barinthus Biotherapeutics, citing promising clinical developments and a strategic merger with Clywedog Therapeutics. The company showed better-than-expected financial management and positive safety results in its Phase 1 AVALON trial. The merger, expected to close in 2026, aims to enhance Barinthus's portfolio, potentially increasing market value. Chen set a price target of $4 per share, supported by ongoing trials and strategic actions.

    Tip Ranks·
    US
    BRNS
    -3.22%
    Tip Ranks·
    US
    BRNS
    -3.22%

    13:55 ET Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights

    Halper Sadeh LLC, an investor rights law firm, is investigating potential violations of federal securities laws involving Nicolet Bankshares, Inc. (NYSE: NIC), Akero Therapeutics, Inc. (NASDAQ: AKRO), and Barinthus Biotherapeutics plc (NASDAQ: BRNS). Shareholders are encouraged to contact the firm to discuss their rights and options regarding these companies' mergers and sales. The firm may seek increased consideration for shareholders and offers legal services on a contingent fee basis. Interested parties can reach out to Halper Sadeh LLC for more information.

    prnewswire·
    US
    NIC
    -3.95%
    US
    BRNS
    -3.22%
    US
    AKRO
    +0.18%
    prnewswire·
    US
    NIC
    -3.95%
    US
    BRNS
    -3.22%
    US
    AKRO
    +0.18%

    17:30 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS

    Class Action Attorney Juan Monteverde of Monteverde & Associates PC is investigating mergers involving Cartica Acquisition Corp. (CRTAF), Akero Therapeutics (AKRO), Adverum Biotechnologies (NIC), and Barinthus Biotherapeutics (BRNS). Shareholder votes are scheduled for November 28, 2025, December 2, 2025, and December 8, 2025, respectively. The firm has a successful track record in recovering funds for shareholders and offers free consultations for those concerned about these transactions.

    prnewswire·
    US
    ADVM
    -0.47%
    US
    BRNS
    -3.22%
    US
    AKRO
    +0.18%
    prnewswire·
    US
    ADVM
    -0.47%
    US
    BRNS
    -3.22%
    US
    AKRO
    +0.18%

    Barinthus Biotherapeutics Reports Q3 2025 Earnings

    Barinthus Biotherapeutics Plc (BRNS) reported its Q3 2025 earnings, revealing a net loss of $14.6 million, up from $8.1 million a year prior, with total revenue dropping to nil from $14.9 million due to the lack of license revenue. Operating expenses decreased to $15.2 million from $24.6 million. The company announced a merger with Clywedog Therapeutics to strengthen its market position and is focused on advancing its lead candidate, VTP-1000, in clinical trials, despite current financial challenges.

    Tip Ranks·
    US
    BRNS
    -3.22%
    Tip Ranks·
    US
    BRNS
    -3.22%

    Barinthus Biotherapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    BRNS
    -3.22%
    LB filings·
    US
    BRNS
    -3.22%